New gout drug epaminurad takes on febuxostat in major trial
NCT ID NCT05815901
First seen Apr 12, 2026 · Last updated May 18, 2026 · Updated 10 times
Summary
This phase 3 trial tested a new gout drug, epaminurad, against the standard treatment febuxostat in 612 adults with gout. The goal was to see which drug better lowers uric acid levels below 6 mg/dL. Participants took one of the two medications for several months, and researchers tracked their uric acid levels and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Inha University Hospital
Incheon, South Korea
Conditions
Explore the condition pages connected to this study.